AcelRx Pharmaceuticals (ACRX) Coverage Initiated by Analysts at B. Riley

Investment analysts at B. Riley initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a report released on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $6.50 price target on the specialty pharmaceutical company’s stock. B. Riley’s price objective points to a potential upside of 68.83% from the company’s current price.

ACRX has been the subject of a number of other research reports. Cantor Fitzgerald set a $9.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, January 29th. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a report on Tuesday, January 8th. LADENBURG THALM/SH SH set a $10.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 8th. BidaskClub upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 1st. Finally, Credit Suisse Group started coverage on shares of AcelRx Pharmaceuticals in a report on Friday, February 15th. They set an “outperform” rating and a $7.00 price objective for the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. AcelRx Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $7.53.

ACRX stock opened at $3.85 on Wednesday. AcelRx Pharmaceuticals has a 12 month low of $1.99 and a 12 month high of $5.05. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.78 and a quick ratio of 6.73. The stock has a market cap of $303.21 million, a P/E ratio of -4.75 and a beta of 2.15.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $3.10 million. As a group, research analysts expect that AcelRx Pharmaceuticals will post -0.88 earnings per share for the current year.

In related news, Director Mark G. Edwards acquired 19,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was bought at an average price of $2.99 per share, for a total transaction of $56,810.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders have purchased a total of 26,721 shares of company stock valued at $78,506 in the last quarter. 25.50% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. Monashee Investment Management LLC raised its holdings in shares of AcelRx Pharmaceuticals by 1,516.8% in the 4th quarter. Monashee Investment Management LLC now owns 1,652,190 shares of the specialty pharmaceutical company’s stock valued at $3,817,000 after purchasing an additional 1,550,000 shares in the last quarter. BlackRock Inc. raised its holdings in shares of AcelRx Pharmaceuticals by 16.8% in the 3rd quarter. BlackRock Inc. now owns 786,034 shares of the specialty pharmaceutical company’s stock valued at $3,026,000 after purchasing an additional 112,919 shares in the last quarter. Cedar Wealth Management LLC raised its holdings in shares of AcelRx Pharmaceuticals by 36.9% in the 4th quarter. Cedar Wealth Management LLC now owns 46,395 shares of the specialty pharmaceutical company’s stock valued at $107,000 after purchasing an additional 12,500 shares in the last quarter. Vanguard Group Inc raised its holdings in shares of AcelRx Pharmaceuticals by 26.3% in the 3rd quarter. Vanguard Group Inc now owns 2,085,556 shares of the specialty pharmaceutical company’s stock valued at $8,030,000 after purchasing an additional 433,969 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of AcelRx Pharmaceuticals by 26.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,085,556 shares of the specialty pharmaceutical company’s stock valued at $8,030,000 after purchasing an additional 433,969 shares in the last quarter. Institutional investors and hedge funds own 18.92% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Article: How to interpret the current ratio

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.